Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors
Gellibert, F., Fouchet, M.-H., Nguyen, V.-L., Wang, R., Krysa, G., de Gouville, A.-C., Huet, S., Dodic, N.(2009) Bioorg Med Chem Lett 19: 2277-2281
- PubMed: 19285388 
- DOI: https://doi.org/10.1016/j.bmcl.2009.02.087
- Primary Citation of Related Structures:  
3GXL, 3HMM - PubMed Abstract: 
Starting from quinazoline 3a, we designed potent and selective ALK5 inhibitors over p38MAP kinase from a rational drug design approach based on co-crystal structures in the human ALK5 kinase domain. The quinazoline 3d exhibited also in vivo activity in an acute rat model of DMN-induced liver fibrosis when administered orally at 5mg/kg (bid).
Organizational Affiliation: 
GlaxoSmithKline, Les Ulis, France. francoise.gellibert@gsk.com